

ASX Release

SUDA 2018 ANNUAL GENERAL MEETING PRESENTATION

PERTH, AUSTRALIA – 15 November 2018: SUDA Pharmaceuticals Ltd (ASX: SUD) announces that the Company's 2018 Annual General Meeting will be held today at 10:30am (GMT+8) at the Boulevard Centre in Floreat, Western Australia.

The following presentation will be given at the Meeting.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 5555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e. cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. ZolpiMist is partnered with Eddingpharm in China and Teva Pharmaceuticals in Latin America. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com

SUDA

PHARMACEUTICALS LTD

Drug delivery through the oral mucosa

Putting the Pieces in Place

David Phillips

November 15th 2018

DISCLAIMER

The purpose of the presentation is to provide an update of the business of SUDA PHARMACEUTICALS LTD (ASX:SUD) ['SUDA']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by SUDA and should not be relied upon as an independent source of information. Please contact SUDA and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside SUDA's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and SUDA's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by SUDA. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

2017/18 Highlights

Date	Description
5th July 2017	Teva license deal
28 th November 2017	Acquisition of Anagrelide
27 th February 2018	Divestment of Westcoast Surgical and Medical
9th April 2018	Appointment of David Phillips to board
2 nd July 2018	Settlement of HC Berlin Pharma litigation
2 nd August 2018	Recapitalisation and debt reduction
21 st August 2018	TGA GMP license
11 th October 2018	Appointment of Andrew Curtis as VP BD&L
8 th November 2018	Strides US agreement

Business Development

Putting the Pieces in Place

- **Building Global Brand Recognition**
- **Refocussed BD approach**
 - Experienced Team
 - Highly Targeted
 - Solid Desk Research and analysis
 - Focussed BD meetings
 - Rigorous Follow up
 - Target Snr Decision makers
 - Developing USA Foot print
 - Andrew Curtis




Andrew Curtis

VP Business Development & Alliance Management

- ✓ **>20 years professional experience at both big pharma and biotech start-ups- Merck, J&J, Pfizer, Sanofi, Jerini, Rising Tide Therapeutics, Affimed**
- ✓ **Extensive experience across therapeutic classes- Rare Diseases, Oncology, CNS, Pain, Wound Healing, Biosimilars,**
- ✓ **Functional roles include Sales and Marketing, Commercial Development, Corporate Strategy, Business Development, Business Unit Leadership**
- ✓ **US home office well-positioned in PA-NJ-NY-MA Pharma/Biotech corridor for efficient access to decisionmakers**



Treatment Evolved: Building the Bridge Between Australia and the US Market




Video Presentation by Andrew Curtis

Can be viewed on <http://sudapharma.com/index.php/media-news>



Piece by Piece




Countries covered by current deals

- Five deals signed
- Teva, Eddingpharm, Strides, Pfizer and Kwang Dong
- Three Products and one development deal
- More deals imminent




Countries with ZolpiMist™ deals complete or in negotiation

- Two signed deals
- Strong interest from a number of Mid and Large Pharmaceutical companies
- Single and Multi territory deals
- Late stage negotiations at agreement stage
- Long term revenue through royalties



Deal Structure


- Focused on upfront - Cash is King
- Achievable Milestones
- Premium on manufacturing can match or exceed the royalty
- Royalty can change the long-term financial profile of the company





Strides Deal

- **Sumatriptan for US Market**
- **ROFR in selected other markets**
- **\$1.4Mn Upfront and Milestones**
- **Fully Funded Development**
- **Royalty and handling Fee**
- **Indian Market saw significant value in deal.**
 - **+11.35% increase in Strides Share price equating to approx. \$85Mn increase in M.cap on day of announcement**



What to look out for in 2019

- **Our focus is on deal closure**
 - **ZolpiMist:** continue to develop the global brand by expanding the geographic territories covered by licensing deals
 - **Sumatriptan:** expand territories covered.
 - **ArTiMist:** Leverage the TGA approval to finalise deal
 - **Anagrelide:** Continue the industry exposure and launch BD activities in earnest
 - **Midazolam:** complete PoC study and convert the strong current interest into deals
 - **Cannabinoids:** Finalise current negotiations and sign deal.
 - **Co-Development:** Complete at least 2 further co-development deals.
 - **Others:** continue to move programs forward to close deals.
- **Close deal- strengthens balance sheet and extends cash runway.**
- **THE PIECES ARE COMING TOGETHER**





Level 1, Unit 12,
55 Howe Street
Osborne Park,
Western Australia 6017
PO Box 1719
Osborne Park BC, WA 6916

(T) +61 8 6142 5555
(F) +61 8 9443 8858
(E) info@sudapharma.com